DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Porphyria cutanea tarda

Essential points for quick revision.

!
PCT with acute liver or skin complication

Jaundice, coagulopathy, ascites, confusion, gastrointestinal bleeding or sepsis around fragile erosions signals liver decompensation or invasive infection rather than uncomplicated cutaneous porphyria.

Action: Assess observations, liver synthesis, glucose, renal function and infection immediately and admit through the acute liver or sepsis pathway; porphyrin confirmation and long-term trigger treatment proceed in parallel, not before stabilisation.

Synopsis

Recognise painless photosensitive hand fragility, confirm a porphyrin rather than acute-porphyria pattern, identify hepatic and iron drivers, and use venesection or low-dose hydroxychloroquine safely.

  • Porphyria cutanea tarda causes painless skin fragility, vesicles and tense bullae on sun-exposed backs of hands and forearms, followed by crust, milia, scarring and pigment change.
  • Facial hypertrichosis and hyperpigmentation can accompany the hand disease; erythema may be minimal and ordinary window glass does not block all porphyrin-activating visible light.
  • Reduced hepatic uroporphyrinogen decarboxylase activity permits oxidised porphyrins to accumulate, circulate and absorb light energy in superficial skin vessels.

Key red flags

Painful inflamed blisters, extensive mucosal disease, neuropathy or abdominal crisis symptoms are atypical for porphyria cutanea tarda, while jaundice, weight loss, hepatomegaly, ascites or cognitive change requires expedited hepatic assessment.

Liver-disease warning

Jaundice, ascites, hepatomegaly, splenomegaly, weight loss, bleeding or encephalopathy demands expedited liver assessment beyond routine PCT care.

Investigation priorities

01
Urine and plasma total porphyrinsFirst step

Demonstrate substantial porphyrin excess using specimens protected from light.

Management branches

First diagnostic sequenceConfirm porphyrins and map hepatic drivers

Painless sun-exposed hand fragility, bullae, milia or facial hypertrichosis suggests PCT.

  1. Document exposure distribution, trauma, urine colour, alcohol, smoking, oestrogen, iron, medicines and liver or neurovisceral symptoms and photograph representative lesions with consent.
  2. Send light-protected urine and plasma for porphyrin quantification and specialist fractionation, adding faecal analysis and acute porphobilinogen only when the laboratory or phenotype indicates.
Preferred iron reductionUse serial venesection to biochemical remission

PCT is confirmed and venesection is feasible without limiting anaemia or vascular-access problems.

Key medicines

Low-dose hydroxychloroquine for PCTTake 100 mg by mouth twice weekly under a specialist porphyria regimen until biochemical remission, then stop according to porphyrin and liver response.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom